Dosing variability with pre-filled syringes of aflibercept presents risk of overdose

Article

Dr Roger A. Goldberg, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

Dosing variability with pre-filled syringes of aflibercept presents risk of overdose

There is a potential for overdosing of aflibercept (Eylea, Regeneron) resulting from small misalignments of the plunger when administering the drug in prefilled syringes, according to Roger A. Goldberg, MD, MBA, in private practice in Walnut Creek, California.

Goldberg presented the information at the American Academy of Ophthalmology 2021 annual meeting in New Orleans.

According to Goldberg, this can lead to a doubling of the volume delivered using these plungers, and this is likely due to the internal diameter of the syringes and the wide dose mark thickness.

This overdosing is probably the culprit in the increasing reports of intraocular pressure (IOP) elevations and transient central retinal artery occlusion since the syringes came into use in August 2019.

The prefilled syringes were designed to store and deliver aflibercept 2.0 mg/0.05 mL. The product is packaged as a 1-mL glass syringe with a domed-plunger tip and a dose mark to facilitate proper volume delivery for intravitreal injection, he described.

Goldberg performed a study of the characteristics and design of the prefilled syringes and tested the delivered dose across a range of potential plunger settings for the aflibercept prefilled syringes.

Images of plunger / dose mark alignment strategies. (a) ranibizumab PFS with plunger aligned according to IFU (condition 1) (b) ranibizumab PFS with plunger cone tip aligned to dose mark (condition 2) (c) aflibercept PFS with plunger aligned according to IFU (condition 3) (d) aflibercept PFS with leading plunger rib aligned to top (distal to needle) edge of dose mark (condition 4) (e) aflibercept PFS with plunger cone tip aligned to top (distal from needle) edge of dose mark (condition 5).

Images of plunger / dose mark alignment strategies. (a) ranibizumab PFS with plunger aligned according to IFU (condition 1) (b) ranibizumab PFS with plunger cone tip aligned to dose mark (condition 2) (c) aflibercept PFS with plunger aligned according to IFU (condition 3) (d) aflibercept PFS with leading plunger rib aligned to top (distal to needle) edge of dose mark (condition 4) (e) aflibercept PFS with plunger cone tip aligned to top (distal from needle) edge of dose mark (condition 5). (Images courtesy of Dr Roger A. Goldberg)

Using purified water, he assessed 3 potential syringe settings in 15 syringes: 1, plunger base aligned to proximal edge of dose mark (the manufacturer’s instruction for use); 2, plunger base aligned to distal edge of dose mark; and 3, plunger tip aligned to distal edge of dose mark.

“The internal diameter of the aflibercept prefilled syringe is 6.35 mm, leading to a volume delivered of 31.7 uL/mm,” Goldberg said. “Digital calliper measurement of the dose mark revealed a thickness of 0.75 mm, leading to a potential dosing error due to the dose mark thickness of 23.8 uL. Dose-delivery testing showed the respective averages ± standard deviations delivered dose across scenarios 1, 2, and 3: 54.8 ± 5.7 uL 78.9 ± 5.7 uL, and 109.7 ±3.4 uL.”

These differences reached significance (p < 0.05).

“Small plunger misalignments can lead to administration of double the volume of aflibercept delivered using the aflibercept prefilled syringe, which likely account for the increased reports of IOP elevation since its launch. Proper adherence to the IFU [instructions for use] can minimize dosing errors.”

Related Content: Additional AAO content | Retina | Inflammation & Infection

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.